Effect of Exercise on the Human Skeletal Muscle Phosphoproteome

Generally, resistance exercise increases muscle mass and strength, and fatigue resistance. How resistance exercise achieves these adaptations remains understudied, but what is known is that skeletal muscle translates the physical and biochemical stresses of resistance exercise into morphological and metabolic adaptations. While resistance exercise activates signaling pathways (i.e., proteins) that increase the synthesis of specific proteins to cause adaptations, thousands of proteins are likely involved, and their interactions are complicated. The investigators aim to study these processes.

Study Overview

• Status: Completed
• Conditions: Skeletal Muscle Protein Synthesis
• Intervention / Treatment: Behavioral: Exercise

Detailed Description

Skeletal muscle is a highly plastic tissue, capable of adapting to changes in nutritional intake and contractile activity. For instance, resistance exercise results in a mild stimulation of rates of muscle protein breakdown (MPB) but a greater stimulation of the rates of muscle protein synthesis (MPS). When resistance exercise is performed prior to protein ingestion there is a synergistic combination of the two stimuli such that rates of MPS are stimulated over and above those of MPB. Thus, repeated bouts of resistance exercise, when coupled with protein ingestion, result in the accretion of skeletal muscle protein referred to as hypertrophy. Importantly, by changing the nature of the exercise stimulus, it is possible to redirect the focus of the type of skeletal muscle proteins that are being synthesized. For example, prolonged and repeated lower-load dynamic stimulation of skeletal muscle (i.e., endurance exercise training) results in an increase in the expression of mitochondrial genes, proteins, and ultimately enhanced mitochondrial content, leading to a shift towards an oxidative phenotype, and improved fatigue resistance. Resistance exercise training also stimulates the transcription of genes and accrual of new muscle proteins, but these genes and proteins are largely associated with the myofibrillar protein fraction, and regular resistance exercise leads to muscle hypertrophy and increased force-generating capacity. However, during the early stages of exercise training, particularly in training-naïve participants there is a significant increase in the expression of genes common to both modalities of exercise. It is only with sustained exercise training that there is a 'fine-tuning' of the transcriptome, the protein synthetic response, and then the proteome that gives rise to divergent hypertrophic and oxidative phenotypes.

• Study Type: Interventional
• Enrollment (Actual): 16
• Phase: Not Applicable

Contacts and Locations

Study Locations

• Canada
  • Ontario
    • Hamilton, Ontario, Canada, L8S 4K1
      • Exercise Metabolism Research Laboratory, McMaster Univeristy

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years to 30 years (Adult)
• Accepts Healthy Volunteers: Yes

Description

Inclusion Criteria:

- between the ages of 18 and 30 years

Exclusion Criteria:

• Smoker or user of tobacco products;
• High physical activity
• Have health problems such as: renal or gastrointestinal disorders, metabolic disease, heart disease, vascular disease, rheumatoid arthritis, diabetes, poor lung function, uncontrolled blood pressure, dizziness, thyroid problems, or any other health conditions for which you are being treated that might put you at risk for this study;
• Taking anti-diabetic, anti-inflammatory, platelet inhibitor, or anti-coagulant medications;
• Use of an investigational drug product within the last 30 days;
• Have participated in an infusion protocol in the last year; or
• Do not understand English or have a condition the PI believes would interfere with a participants' ability to provide informed consent, comply with the study protocol, or which might confound the interpretation of the study results or put someone at undue risk.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Basic Science
• Allocation: N/A
• Interventional Model: Single Group Assignment
• Masking: None (Open Label)

Number of Arms

1

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: Exercise; All subjects will perform both aerobic and resistance exercise	Behavioral: Exercise; Aerobic exercise and resistance exercise

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Change in Acute Muscle Protein Synthesis	Myofibrillar and intracellular enrichments of L-[ring- 13C6] phenylalanine will be measured. MPS will be calculated using the precursor-product equation: MPS =([E2b-E1b]/[Eic x t]) x 100. Eb represents the enrichment of bound myofibrillar protein, Eic is the average intracellular enrichment between two biopsies, and t is the tracer incorporation time in h. As we will employ 'tracer naïve' participants (had not previously participated in a study protocol where L-[ring- 13C6] phenylalanine was infused), a pre-infusion blood sample will be used for the calculation of resting myofibrillar MPS. The outcomes measure will be expressed as a percentage change of MPS relative to the baseline measure. i.e. intracellular enrichment of L-[ring- 13C6] phenylalanine relative to the baseline (resting) period.	Pre exercise (resting) to 3 hours post-exercise

Collaborators and Investigators

• Sponsor: McMaster University
• Investigators: Principal Investigator: Stuart Phillips, PhD, McMaster University, Department of Kinesiology

Study record dates

Study Major Dates

• Study Start (Actual): April 1, 2020
• Primary Completion (Actual): July 1, 2023
• Study Completion (Actual): May 1, 2024

Study Registration Dates

• First Submitted: February 5, 2020
• First Submitted That Met QC Criteria: February 10, 2020
• First Posted (Actual): February 11, 2020

Study Record Updates

• Last Update Posted (Actual): November 21, 2024
• Last Update Submitted That Met QC Criteria: November 14, 2024
• Last Verified: November 1, 2024

More Information

Terms related to this study

• Other Study ID Numbers: 2196

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: YES
• IPD Plan Description: All data will be deposited on OSF
• IPD Sharing Time Frame: At the time of publication
• IPD Sharing Access Criteria: Everyone can access
• IPD Sharing Supporting Information Type: STUDY_PROTOCOL; CSR

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No